Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4244893
Max Phase: Preclinical
Molecular Formula: C52H99N17O10
Molecular Weight: 1122.47
Molecule Type: Small molecule
Associated Items:
ID: ALA4244893
Max Phase: Preclinical
Molecular Formula: C52H99N17O10
Molecular Weight: 1122.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(N)=O)C(C)C
Standard InChI: InChI=1S/C52H99N17O10/c1-27(2)23-37(62-33(12)70)46(75)66-39(25-29(5)6)48(77)68-40(26-30(7)8)49(78)67-38(24-28(3)4)47(76)64-36(19-16-22-60-52(57)58)45(74)69-41(31(9)10)50(79)65-34(17-13-14-20-53)44(73)63-35(18-15-21-59-51(55)56)43(72)61-32(11)42(54)71/h27-32,34-41H,13-26,53H2,1-12H3,(H2,54,71)(H,61,72)(H,62,70)(H,63,73)(H,64,76)(H,65,79)(H,66,75)(H,67,78)(H,68,77)(H,69,74)(H4,55,56,59)(H4,57,58,60)/t32-,34-,35-,36-,37-,38-,39-,40-,41-/m0/s1
Standard InChI Key: WTTSARPTGKTHMH-YEBJWTNYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1122.47 | Molecular Weight (Monoisotopic): 1121.7761 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.. (2018) Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines., 61 (18): [PMID:30180568] [10.1021/acs.jmedchem.8b01144] |
Source(1):